作为HR+/ HER2早期乳腺癌的辅助治疗, NCCN将利博西基布指定为首选治疗方案,增加了符合条件的患者. NCCN designates ribociclib as preferred adjuvant treatment for HR+/HER2- early breast cancer, increasing eligible patients.
国家综合癌症网络已指定Nivartis' ribociclib(Kisqali)为第1类对荷尔蒙受体阳性/人类上皮瘤生长因子受体2-阴性早期乳腺癌的首选辅助治疗。 The National Comprehensive Cancer Network (NCCN) has designated Novartis' ribociclib (Kisqali®) as a Category 1 preferred adjuvant treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer. 根据更新的准则,这种承认使更多的病人在使用芳香酶抑制剂时能够从这种治疗中受益,使在这种情况下CDK4/6抑制剂的合格病人人数实际上翻了一番。 This recognition, based on updated guidelines, allows more patients to benefit from this treatment when used with an aromatase inhibitor, effectively doubling the eligible patient population for CDK4/6 inhibitors in this context.